CLINICAL TRIALS PROFILE FOR DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

All Clinical Trials for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001059 ↗	Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS	Completed	Amgen	Phase 2	1969-12-31	To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life. Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.
NCT00001059 ↗	Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS	Completed	Sequus Pharmaceuticals	Phase 2	1969-12-31	To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life. Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.
NCT00001059 ↗	Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life. Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.
NCT00002093 ↗	A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.	Completed	Nexstar Pharmaceuticals	Phase 3	1969-12-31	To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered in combination with antiretroviral therapy. To compare the duration of responses, response rates, and times to response.
NCT00002105 ↗	Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma	Completed	Sequus Pharmaceuticals	Phase 3	1969-12-31	To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy BV (bleomycin/vincristine). To evaluate the safety and tolerance of DOX-SL compared to BV in a population of AIDS patients with moderate to severe KS.

Clinical Trial Conditions for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

Condition Name

Condition Name for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Intervention	Trials
Ovarian Cancer	67
Breast Cancer	56
Fallopian Tube Cancer	29
Multiple Myeloma	24

Condition MeSH

Condition MeSH for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Intervention	Trials
Ovarian Neoplasms	126
Carcinoma, Ovarian Epithelial	100
Breast Neoplasms	81
Fallopian Tube Neoplasms	56

Clinical Trial Locations for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

Trials by Country

Trials by Country for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Location	Trials
Italy	135
China	77
Spain	63
Germany	57
Canada	52

Trials by US State

Trials by US State for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Location	Trials
California	78
New York	67
Texas	58
Florida	50
Ohio	49

Clinical Trial Progress for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

Clinical Trial Phase

Clinical Trial Phase for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	65
Phase 2/Phase 3	8

Clinical Trial Status

Clinical Trial Status for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Clinical Trial Phase	Trials
Completed	170
Terminated	52
Recruiting	51

Clinical Trial Sponsors for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

Sponsor Name

Sponsor Name for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Sponsor	Trials
National Cancer Institute (NCI)	67
Merck Sharp & Dohme Corp.	12
M.D. Anderson Cancer Center	12

Sponsor Type

Sponsor Type for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Sponsor	Trials
Other	395
Industry	247
NIH	70